Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bath & Body Works Inc (BBWI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bath & Body Works Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Bath & Body Works Inc trades at $20.33 (market cap $4.10B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 9.7× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays a 3.94% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BBWI | |
|---|---|---|
Market Cap | $39.89B | $4.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $33.11 |
52-Week Low | $278.09 | $14.85 |
Enterprise Value | $38.15B | $7.99B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BBWI trades at $20.33, up 2.01% today, with a bearish technical signal but neutral oscillators. The stock shows strong profitability with a net margin of 10.03% and attractive valuation ratios, including a P/E of 5.78. Recent earnings beat expectations in Q1 2026, and the company's partnership with Ulta Beauty aims to expand reach. Cash flow trends indicate improving net cash flow by 2026, though the balance sheet carries significant debt.
The outlook is mixed: analyst consensus is a Buy with a $22.00 price target, suggesting upside, but risks include declining revenue over five years and high leverage. The Ulta partnership and cost-saving initiatives offer growth potential, yet competitive pressures and macroeconomic headwinds pose challenges for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →
